Journal of Antimicrobial Chemotherapy (1995) 35, 399-408
© 1995 The British Society for Antimicrobial Chemotherapy
research-article |
A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel
aPreventative Medicine Department, San Carlos University Hospital, Professor Martín Lagos s/n 28040, Madrid, Spain bMedical Department, SmithKline Beecham, S.A. Valle de la Fuenfria no 3, 28034 Madrid, Spain cStaphylococcal Reference Laboratory of the Carlos III Health Institute, Crta de Majadahonda Pozuelo Km 2 28220 Majadahonda, Madrid, Spain
Received 8 February 1994; returned 9 May 1994; accepted 26 September 1994
Sixty-eight health care workers were enrolled in a double-blind clinical trial and randomized to receive either mupirocin calcium ointment or placebo, intranasally bid for 5 days. Nasal cultures were taken immediately before starting treatment, 1 and 2 during treatment, at the end of treatment, 3 days later, weekly for 15 weeks and then monthly for 26 months after treatment. Mupirocin eliminated nasal carriage with Staphylococcus aureus in 58% of subjects within two days and 86·7% subjects by the end of therapy compared to 9·4% subjects at the end oftreatment with placebo (P < 0.001). Post-treatment colonization rates of 43%, 56% and 67% were attained after 1 month, 24 and 6 months treatment with mupirocin respectively and recolonisation with the same strain of S. aureus that had been isolated before treatment was noted in 32%, 40% and 48%. No resistance to mupirocin developed and the drug was well tolerated. Mupirocin is safe and effective in suppressing nasalcarriage of S. aureus.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. Coates, R. Bax, and A. Coates Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects J. Antimicrob. Chemother., July 1, 2009; 64(1): 9 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Shrestha, M. K. Banbury, M. Weber, R. E. Cwynar, C. Lober, G. W. Procop, M. T. Karafa, and S. M. Gordon Safety of Targeted Perioperative Mupirocin Treatment for Preventing Infections After Cardiac Surgery Ann. Thorac. Surg., June 1, 2006; 81(6): 2183 - 2188. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F.L. Wertheim, M. C. Vos, A. Ott, A. Voss, J. A.J.W. Kluytmans, C. M.J.E. Vandenbroucke-Grauls, M. H.M. Meester, P. H.J. van Keulen, and H. A. Verbrugh Mupirocin Prophylaxis against Nosocomial Staphylococcus aureus Infections in Nonsurgical Patients: A Randomized Study Ann Intern Med, March 16, 2004; 140(6): 419 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Upton, S. Lang, and H. Heffernan Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance J. Antimicrob. Chemother., March 1, 2003; 51(3): 613 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gisby and J. Bryant Efficacy of a New Cream Formulation of Mupirocin: Comparison with Oral and Topical Agents in Experimental Skin Infections Antimicrob. Agents Chemother., February 1, 2000; 44(2): 255 - 260. [Abstract] [Full Text] |
||||



